16 completed, 7 recruiting, 5 terminated, 4 active not recruiting. 39 Phase 1, 18 Phase 2.
Follow Thyroid Cancer: new trials by email Literature Review of Thyroid Cancer trials Research Report on Thyroid Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer 68Ga-DOTA-TATE PET Scan, Amino acid infusions, 177Lu-DOTA-EB-TATE - Thyroid Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 18 | 2026-11-18 | 2026-11-13 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer 177Lu-CTR-FAPI therapy - Thyroid Cancer | Phase 1 | Recruiting | SHAOYAN LIU | 12 | 2026-01-01 | 2026-02-27 |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation XP-102, Trametinib - Cancer, BRAF V600 Mutation | Phase 1 / Phase 2 | Not yet recruiting | Xynomic Pharmaceuticals, Inc. | 221 | 2025-12-31 | 2025-04-10 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| XL092 and Cemiplimab in BRAF WT Thyroid Cancer Cemiplimab, XL092 - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2025-06-03 | 2026-10-05 |
| Brodalumab in the Treatment of Immune-Related Adverse Events Brodalumab, CT scan - Breast Cancer, Esophageal Cancer | Phase 1 | Recruiting | Brian Henick, MD | 11 | 2025-03-11 | 2026-05-13 |
| Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron - Tumor, Solid, Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan Enray Pharmaceutical Sciences Company | 54 | 2024-11-12 | 2026-02-25 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) Three-dimensional patient-specific bioprinting trachea implantation - Thyroid Cancer | Phase 1 / Phase 2 | Unknown | Ja Seong Bae, MD, phD | 1 | 2023-07-17 | 2023-09-25 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery Oxidized regenerated cellulose(ORC), Hyaluronic acid(HA) - Thyroidectomy, Goiter | Phase 1 | Completed | National Taiwan University Hospital | 45 | 2023-05-24 | 2025-09-19 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Kineta Inc. | 40 | 2023-03-03 | 2026-10-05 |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors PF-07799544, PF-07799933 - Melanoma, Glioma | Phase 1 | Active not recruiting | Pfizer | 148 | 2022-11-30 | 2026-09-01 |
| Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg - Advanced Solid Tumor, Lung Cancer | Phase 1 | Completed | Sichuan Enray Pharmaceutical Sciences Company | 19 | 2022-11-17 | 2025-08-03 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 263 | 2022-10-17 | 2024-10-15 |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. PF-07799933, binimetinib, cetuximab - Melanoma, Non-Small-Cell Lung Cancer | Phase 1 | Active not recruiting | Pfizer | 103 | 2022-07-05 | 2026-09-01 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel - Advanced Solid Tumor, Cholangiocarcinoma | Phase 1 / Phase 2 | Completed | TransThera Sciences (Nanjing), Inc. | 84 | 2022-04-13 | 2025-06-12 |
| Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer Targeted alpha therapy - Thyroid Cancer | Phase 1 | Completed | Osaka University | 11 | 2021-11-20 | 2025-04-24 |
Showing 20 of 39. Sign in to see all of them.
Thyroid Neoplasms (39) · Melanoma (14) · Carcinoma, Non-Small-Cell Lung (13) · Breast Neoplasms (12) · Prostatic Neoplasms (11) · Ovarian Neoplasms (10) · Pancreatic Neoplasms (10) · Sarcoma (10) · Stomach Neoplasms (10) · Lung Neoplasms (8) · Colonic Neoplasms (7) · Neoplasms (7) · Small Cell Lung Carcinoma (7) · Uterine Cervical Neoplasms (7) · Colorectal Neoplasms (6)
Endocrine Gland Neoplasms (39) · Endocrine System Diseases (39) · Neoplasms by Site (39) · Thyroid Diseases (38) · Head and Neck Neoplasms (34) · Neoplasms (32) · Neoplasms by Histologic Type (25) · Respiratory Tract Diseases (25) · Lung Diseases (24) · Respiratory Tract Neoplasms (24) · Thoracic Neoplasms (24) · Neoplasms, Glandular and Epithelial (23) · Skin Diseases (23) · Skin and Connective Tissue Diseases (23) · Carcinoma (20)
pembrolizumab (3) · 130-nm albumin-bound paclitaxel (2) · Cetuximab (2) · Vemurafenib (2) · cemiplimab (2) · trametinib (2) · (177)Lu-DOTA-EB-TATE (1) · ALT-803 (1) · Azacitidine (1) · Biopsy (1) · Capecitabine (1) · Clinical Trials, Phase II as Topic (1) · Cyclophosphamide (1) · Dacarbazine (1) · Fluorodeoxyglucose F18 (1)
Memorial Sloan Kettering Cancer Center (4) · Pfizer (2) · Sichuan Enray Pharmaceutical Sciences Company (2) · TransThera Sciences (Nanjing), Inc. (2) · Anusha Kalbasi (1) · Brian Henick, MD (1) · Celgene (1) · Celldex Therapeutics (1) · Dana-Farber Cancer Institute (1) · Fore Biotherapeutics (1) · Genmab (1) · Institut Bergonié (1) · Institut de Recherches Internationales Servier (1) · Ja Seong Bae, MD, phD (1) · Jewish General Hospital (1)
United States (26) · China (6) · Canada (5) · Spain (4) · Australia (3) · France (3) · Japan (3) · Belgium (2) · Denmark (2) · Israel (2) · United Kingdom (2) · Brazil (1) · Czechia (1) · Hong Kong (1) · Italy (1)
Alan L Ho, MD, PhD (1) · Allison Betof Warner, MD, PhD (1) · Antoni Ribas, MD, PhD (1) · Brian Henick, MD (1) · Du Lam, MD (1) · Funda Meric-Burnstam, MD (1) · Ignace Vergote, Professor (1) · James Yao, MD (1) · Jason Koutcher, MD, PhD (1) · Joanna Klubo-Gwiezdzinska, M.D. (1) · Kartik Seghal, MD (1) · Melissa Henry, PhD (1) · Ming Hsun Wu (1)
PMID 25086465, PMID 26041482, PMID 26163763, PMID 27240885, PMID 28744123, PMID 29186019, PMID 30184767, PMID 30261427, PMID 32510916, PMID 34766118, PMID 34965951, PMID 34998048, PMID 35045748, PMID 37171634, PMID 40204996, PMID 40579407, PMID 40613790, PMID 41495607, PMID 42249319, PMID 42816483
2016 (2), 2018 (1), 2025 (1)